Fecal transplants to treat C. diff now need FDA approval
By
McKnight's Staff
May 17, 2013
The Food and Drug Administration is moving to tighten regulations around fecal transplants, which research has shown to be an effective treatment for Clostridium difficile infection.
FDA warns of heart-related events for arthritis drug Xeljanz and others in its class
By
Alicia Lasek
Sep 02, 2021
The agency is requiring a warning label on the arthritis and ulcerative colitis drugs Xeljanz and Xeljanz XR (tofacitinib) and two other drugs in this class, citing an increased risk of adverse health...
Self-sanitizing keyboard uses ultraviolet light
Jan 04, 2012
Vioguard announced that its self-sanitizing computer keyboard has received marketing clearance from the Food and Drug Administration. The keyboard was developed to address the need for continual disinfection...
Clinical Daily Briefs for Thursday, March 26
By
Alicia Lasek
Mar 25, 2020
Argentum, AHCA / NCAL launch campaigns to share positive messages during pandemic … Clinic study shows where surface-cleaning efforts can fall short … CVS moves to prevent hoarding of malaria drug...
FDA requires abuse warning on Xanax, Valium labels
By
Alicia Lasek
Sep 25, 2020
Benzodiazepine drug labels must now display the FDA’s most serious “boxed warning” following growing reports of sedative abuse, the agency announced Thursday.
Clinical briefs for Thursday, Oct. 14
By
Alicia Lasek
Oct 14, 2021
New CDC effort will track impact of COVID-19 and other public health threats on long-term care facilities … FDA pushes to cut sodium by 12% in American foods in bid to confront chronic disease epidemic...
Clinical briefs for Thursday, June 10
By
Alicia Lasek
Jun 10, 2021
Operator changes plans, will wait for full FDA approval to enforce COVID vaccination deadline among staff … Colorado drops mask mandate for assisted living communities … FDA panel member resigns over...
U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
Providers call for broader antipsychotic exclusions to help reduce schizophrenia diagnoses
By
Kimberly Marselas
Mar 31, 2023
Providers and quality experts are questioning why the agency hasn’t done more to review its quality measure for antipsychotic drug use.
BD investigating reports of false positives from COVID-19 tests
By
Danielle Brown
Sep 16, 2020
New Jersey-based medical technology company Becton Dickinson, or BD, is conducting an investigation following reports that its COVID-19 point-of-care testing equipment is producing false positive results...